Mohamed Hegazi is an Oncology physician. OpenAlex indexes 53 publications with 413 citations (h-index 12).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
529 S Jackson St
Louisville, KY 40202
Telephone
502-562-4270Registry record last updated 19 Oct 2018.
Industry payments
52 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- BeOne Medicines USA, Inc.Program year202539 payments$45,534openpaymentsdata.cms.gov ↗
- Syndax Pharmaceuticals, Inc.Program year202530 payments$36,724openpaymentsdata.cms.gov ↗
- Janssen Biotech, Inc.Program year202527 payments$18,373openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
45.4%Kinase inhibitor24.3%Brukinsa30%Imatinib Mesylate23%Sprycel14%Imbruvica13%Jakafi12%Calquence8%Part D<11 patientsThalidomide Analog11.2%Revlimid61%Lenalidomide39%Part D<11 patients+ 3 more classes in this area
Nervous system
16%Gabapentinoids13.4%Gabapentin81%Pregabalin19%Part D<11 patientsPhenothiazine2.6%Prochlorperazine Maleate100%Part D<11 patientsDermatology
14.9%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor14.9%Acyclovir100%Part D≥26 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- The Effectiveness of Rifapentine-Isoniazid in the Prevention of Tuberculosis Among HIV Infected Patients: A Systematic Review and Meta-analysis of Non-inferiority Randomized Trials
American Journal of Respiratory and Critical Care Medicine
2025 - Managing a Drip Irrigation System to Maximize Potato Crop Productivity Using Nano-Phosphate in Sandy Soil
Arab Universities Journal of Agricultural Sciences
2025 - Unveiling Immediate Pseudo-Progression with Epcoritamab in Lymphoma Treatment: Case Series Exploration
Biology of Blood and Marrow Transplantation
2024 - Is there a potential dual effect of denosumab for treatment of osteoporosis and sarcopenia?
Clinical Rheumatology
2021
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”